Released Mar 20, 2019, after the close
10-K filed Mar 22, 2019, 81 days after period end · 0001493152-19-003770
Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.92M$5.92M derived+11.8% vs Q4 2017−1.4% vs Q3 2018
Net Income$52.00K$52.00K derivedN/M vs Q4 2017−76.6% vs Q3 2018
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$173,000N/M
Operating Cash Flowderived$837,000N/M
Free Cash Flowderived$480,000N/M
Margins · derived
Operating margin2.9%+12.2 pt vs Q4 2017
Net margin0.9%+12.9 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.92M | $5.30M | $5.98M | $6.52M |
| Net Income | $52.00K | -$639.00K | -$459.00K | -$990.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR